Drug Profile
ICI 200880
Alternative Names: ICI200880Latest Information Update: 07 Apr 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Anti-ischaemics; Surfactants
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Cystic fibrosis; Emphysema; Myocardial ischaemia
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 01 Nov 1995 Discontinued-I for Cystic fibrosis in Uganda (Unknown route)
- 01 Nov 1995 Discontinued-I for Cystic fibrosis in United Kingdom (Unknown route)